Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04724031

Enrollment

150

Registered

2021-01-26

Start date

2019-11-01

Completion date

2023-09-30

Last updated

2023-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Brief summary

Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive PARP inhibitors.

Detailed description

A prospective-retrospective analysis of patients with histologically confirmed high grade ovarian cancer who will receive or received olaparib or niraparib will be conducted at any line of treatment.

Interventions

DRUGPARP inhibitor

use at any line of treatment in patients with advanced ovarian cancer

Study design

Observational model

OTHER

Time perspective

OTHER

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 80 Years

Inclusion criteria

\- women \>18 years old with advanced high grade ovarian cancer

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
Evaluation of Progression Free Survival	12/2022

Secondary

Measure	Time frame
Assessment of the safety profile of olaparib in women with advanced high grade ovarian cancer	12/2021
Assessment of the safety profile of niraparib in women with advanced high grade ovarian cancer	12/2021

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026